Ross Lawrenson1, Chunhuan Lao2, Ian Campbell3, Vernon Harvey4, Sanjeewa Seneviratne5, Mark Elwood6, Diana Sarfati7, Marion Kuper-Hommel8. 1. Professor of Population Health, Waikato Medical Research Centre, The University of Waikato, Hamilton. 2. Research Fellow, Waikato Medical Research Centre, The University of Waikato, Hamilton. 3. Associate Professor of Surgery, School of Medicine, The University of Auckland, Auckland. 4. Medical Oncologist, Auckland City Hospital, Auckland. 5. Senior Lecturer, Department of Surgery, Faculty of Medicine, University of Colombo, Sri Lanka. 6. Professor of Cancer Epidemiology, School of Population Health, The University of Auckland, Auckland. 7. Professor of Epidemiology, Department of Public Health, The University of Otago, Wellington. 8. Medical Oncologist, Waikato District Health Board, Hamilton.
Abstract
AIMS: This study aims to describe the prevalence and characteristics of the different ER/PR/HER2 subtypes in New Zealand women with breast cancer, and to explore their treatment and outcomes. METHODS: This study included women diagnosed with Stage I-III breast cancer between January 2006 and May 2013, recorded in the combined Waikato and Auckland Breast Cancer Registers, and with complete data on their ER, PR and HER2 status. Five ER/PR/HER2 phenotypes were classified. Kaplan-Meier method and Cox proportional hazards model were used to examine the survival differences among these subtypes. RESULTS: Of the 6,875 eligible women, 4,274 (62.2%) were classified as Luminal A, 836 (12.2%) as Luminal B HER2-, 605 (8.8%) as Luminal B HER2+, 401 (5.8%) as HER2+ non-Luminal and 759 (11.0%) as Triple Negative. Māori and Pacific women were less likely to have Triple Negative disease, while Pacific women were more likely to be HER2+ non-Luminal. The five-year breast cancer-specific survival was worst for HER2+ non-Luminal (80.1%) and Triple Negative (81.9%), followed by Luminal B HER2- (89.3%) and Luminal B HER2+ (91.6%), and was the best for Luminal A (96.8%). The adjusted breast cancer-specific mortality hazard ratio for Triple Negative and HER2+ non-Luminal compared to Luminal A was 4.91 (95% CI: 3.86-6.26) and 3.94 (95% CI: 2.94-5.30), respectively. CONCLUSIONS: The pattern of phenotype in women with Stage I-III breast cancer is similar to the overseas cohorts. Most New Zealand women with Luminal A breast cancer have a very good prognosis, but the less common subtypes have relatively poor outcomes.
AIMS: This study aims to describe the prevalence and characteristics of the different ER/PR/HER2 subtypes in New Zealand women with breast cancer, and to explore their treatment and outcomes. METHODS: This study included women diagnosed with Stage I-III breast cancer between January 2006 and May 2013, recorded in the combined Waikato and Auckland Breast Cancer Registers, and with complete data on their ER, PR and HER2 status. Five ER/PR/HER2 phenotypes were classified. Kaplan-Meier method and Cox proportional hazards model were used to examine the survival differences among these subtypes. RESULTS: Of the 6,875 eligible women, 4,274 (62.2%) were classified as Luminal A, 836 (12.2%) as Luminal B HER2-, 605 (8.8%) as Luminal B HER2+, 401 (5.8%) as HER2+ non-Luminal and 759 (11.0%) as Triple Negative. Māori and Pacific women were less likely to have Triple Negative disease, while Pacific women were more likely to be HER2+ non-Luminal. The five-year breast cancer-specific survival was worst for HER2+ non-Luminal (80.1%) and Triple Negative (81.9%), followed by Luminal B HER2- (89.3%) and Luminal B HER2+ (91.6%), and was the best for Luminal A (96.8%). The adjusted breast cancer-specific mortality hazard ratio for Triple Negative and HER2+ non-Luminal compared to Luminal A was 4.91 (95% CI: 3.86-6.26) and 3.94 (95% CI: 2.94-5.30), respectively. CONCLUSIONS: The pattern of phenotype in women with Stage I-III breast cancer is similar to the overseas cohorts. Most New Zealand women with Luminal A breast cancer have a very good prognosis, but the less common subtypes have relatively poor outcomes.
Authors: Chunhuan Lao; Marion Kuper-Hommel; Mark Elwood; Ian Campbell; Melissa Edwards; Ross Lawrenson Journal: Breast Cancer Date: 2020-10-12 Impact factor: 4.239
Authors: Chunhuan Lao; Marion Kuper-Hommel; Mark Elwood; Ian Campbell; Ross Lawrenson Journal: Cancer Causes Control Date: 2021-04-08 Impact factor: 2.506
Authors: Oliver William Scott; Sandar Tin Tin; J Mark Elwood; Alana Cavadino; Laurel A Habel; Marion Kuper-Hommel; Ian Campbell; Ross Lawrenson Journal: Breast Cancer Res Treat Date: 2022-03-14 Impact factor: 4.872